• Sign up to our Free Newsletter
  • Contact Us
  • Editorial Submission
Microbiome Times Magazine
  • Human Health
  • Finance
  • Drug Database
    • Login
    • About
  • Issue Archive
  • Advertise
  • Recruitment Marketing

Pharma & Human Health

Pharma & Human Health

New “vertical map” of airborne microorganisms indicates how global warming will impact global ecosystems

February 11, 2022 Microbiome Times

In a landmark study of airborne microorganisms from ground level up to 3,500 metres, scientists from the Singapore Centre for Environmental Life Sciences Engineering (SCELSE) at Nanyang Technological University, Singapore (NTU Singapore) have found that […]

Finance

Armata Pharmaceuticals Announces $45 Million Investment to Support Advancement of the Company’s Bacteriophage Development

February 10, 2022 Microbiome Times

Armata Pharmaceuticals, Inc. (NYSE American: ARMP) (“Armata” or the “Company”), a biotechnology company focused on pathogen-specific bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bacterial infections, announced that it has entered into a securities purchase agreement to […]

Finance

MaaT Pharma and Skyepharma Enter Partnership to Establish Manufacturing Facility for Microbiome Ecosystem Therapies

February 9, 2022 Microbiome Times

MaaT Pharma, a French clinical-stage biotech (Phase 3) and a pioneer in the development of microbiome-based ecosystem therapies dedicated to improving survival outcomes for patients with cancer and Skyepharma, a Contract Development and Manufacturing Organization […]

Pharma & Human Health

BioGaia’s probiotic reduces inflammation in patients with diverticulitis

February 9, 2022 Microbiome Times

A randomized, double-blind, placebo-controlled study with BioGaia’s probiotic strain Limosilactobacillus reuteri ATCC PTA 4659 was shown to reduce inflammation significantly more than placebo in patients with acute uncomplicated diverticulitis. Moreover, as hospitalization time was shorter in the […]

Editor's Choice

ELIGO v SNIPR: a reflection on IP strategies in a competitive environment

February 7, 2022 Craig Thomson and Jennifer Bailey

Introduction In November 2021, US “Interference” proceedings resulted in cancellation of five US patents owned by SNIPR TECHNOLOGIES. It was concluded that the technology claimed in those patents was invented earlier by The Rockefeller University.  […]

Pharma & Human Health

Microbiome of mother’s vagina may affect infant mortality risk and baby’s development

February 4, 2022 Microbiome Times

A new study in mice from University of Maryland School of Medicine researchers showed that an unhealthy vaginal microbiome in pregnant mothers in combination with an unhealthy diet contributed to increased pup deaths and altered […]

Editor's Choice

Ferring takes pre-emptive action in IP dispute with Finch

February 2, 2022 Kristina Campbell

In the relatively young microbiome biotechnology industry, companies aim to distinguish themselves from a growing number of competitors by protecting their intellectual property (IP). As in any new field, initial patent claims tend to be […]

Pharma & Human Health

Publication of ECOSPOR lll Phase 3 Study Data Evaluating SER-109 in Recurrent C. Difficile Infection

January 24, 2022 Microbiome Times

Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced the publication in the New England Journal of Medicine (NEJM) of data from its Phase 3 ECOSPOR III study evaluating SER-109, an investigational […]

Pharma & Human Health

Viruses and game theory

January 13, 2022 Microbiome Times

A new study from Tel Aviv University has found that, just like humans with Game Theory, viruses called bacteriophages (or phages) weigh all options and finally make an informed decision – whether the time has […]

Pharma & Human Health

Researchers discover new hiding place for antibiotic resistance

December 20, 2021 Microbiome Times

Antibiotic resistance is a race between us humans, who strive to find new antibiotics that can treat infectious diseases – and bacteria, which are becoming increasingly resistant. For now, bacteria are way ahead, which is […]

Finance

SGS Acquisition of Quay Pharma Will Further Strengthen Offering

December 16, 2021 Microbiome Times

Quay Pharma, the leading pharmaceutical contract development and manufacturing organisation (CDMO), has been acquired by SGS, the Swiss-based world leading (TIC) Testing, Inspection and Certification company. The deal will provide Quay with the investment to […]

Posts navigation

« 1 … 32 33 34 … 86 »

QIAGEN’S NEW HIGH-THROUGHPUT BENCHTOP AUTOMATION SYSTEM

Sign Up to Free Newsletter

NEW WHITEPAPER: ORAL DELIVERY OF LIVE BIOTHERAPEUTIC PRODUCTS:

Editor’s Choice

  • LACTIN-V: A Promising Live Biotherapeutic for Recurrent Bacterial Vaginosis
    May 1, 2026
  • Lactic Acid’s Untapped Potential to Optimise the Vaginal Microbiota and Mucosal Environment
    April 8, 2026
  • Multi-strain probiotic therapy shows promise in preventing bacterial vaginosis recurrence
    March 24, 2026
  • Microbiotica Announces Impressive Results in its Phase 1b Trial of MB310 in Ulcerative Colitis
    February 11, 2026
  • Immunity as a Lifestyle Priority
    January 30, 2026
sign up

Sign up to the Microbiome Times newsletter